{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:08:35Z","timestamp":1790629715647,"version":"4.1.0"},"reference-count":196,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFB3814800"],"award-info":[{"award-number":["2024YFB3814800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010226","name":"Department of Education of Guangdong Province","doi-asserted-by":"publisher","award":["2024ZDZX2053"],"award-info":[{"award-number":["2024ZDZX2053"]}],"id":[{"id":"10.13039\/501100010226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515012229"],"award-info":[{"award-number":["2024A1515012229"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2023ZYGXZR035"],"award-info":[{"award-number":["2023ZYGXZR035"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372101"],"award-info":[{"award-number":["82372101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32371445"],"award-info":[{"award-number":["32371445"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Municipal Science and Technology Program key projects","doi-asserted-by":"publisher","award":["2024A04J3733"],"award-info":[{"award-number":["2024A04J3733"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.actbio.2025.07.068","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T15:57:20Z","timestamp":1753977440000},"page":"187-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Inhalable nucleic acid therapeutics for chronic pulmonary disease: Progress, challenges, and prospects"],"prefix":"10.1016","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8412-9886","authenticated-orcid":false,"given":"Yangeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7593-9581","authenticated-orcid":false,"given":"Wenzhe","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengqiong","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5691-5758","authenticated-orcid":false,"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10082","key":"10.1016\/j.actbio.2025.07.068_bib0001","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(17)30866-8","article-title":"Idiopathic pulmonary fibrosis","volume":"389","author":"Richeldi","year":"2017","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.actbio.2025.07.068_bib0002","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"10342","key":"10.1016\/j.actbio.2025.07.068_bib0003","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/S0140-6736(22)00470-6","article-title":"Chronic obstructive pulmonary disease","volume":"399","author":"Christenson","year":"2022","journal-title":"Lancet"},{"issue":"10122","key":"10.1016\/j.actbio.2025.07.068_bib0004","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0140-6736(17)33311-1","article-title":"Asthma","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.actbio.2025.07.068_bib0005","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.drudis.2014.09.020","article-title":"Recent advances in controlled pulmonary drug delivery","volume":"20","author":"Liang","year":"2015","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0006","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","article-title":"Chemistry of lipid nanoparticles for RNA delivery","volume":"55","author":"Eygeris","year":"2022","journal-title":"Acc. Chem. Res."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0007","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","article-title":"Advances in COVID-19 mRNA vaccine development","volume":"7","author":"Fang","year":"2022","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"7992","key":"10.1016\/j.actbio.2025.07.068_bib0008","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-023-06809-8","article-title":"Inhaled SARS-CoV-2 vaccine for single-dose dry powder aerosol immunization","volume":"624","author":"Ye","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.actbio.2025.07.068_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2023.101942","article-title":"Inhaled drug delivery: past, present, and future","volume":"52","author":"Yue","year":"2023","journal-title":"Nano Today"},{"key":"10.1016\/j.actbio.2025.07.068_bib0010","article-title":"Pulmonary vaccine delivery: an emerging strategy for vaccination and immunotherapy","volume":"69","author":"Masjedi","year":"2022","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"7","key":"10.1016\/j.actbio.2025.07.068_bib0011","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41551-021-00760-7","article-title":"CRISPR-based diagnostics","volume":"5","author":"Kaminski","year":"2021","journal-title":"Nat. Biomed. Eng."},{"issue":"13","key":"10.1016\/j.actbio.2025.07.068_bib0012","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201901081","article-title":"Cancer-targeting nanoparticles for combinatorial nucleic acid delivery","volume":"32","author":"Vaughan","year":"2020","journal-title":"Adv. Mater."},{"issue":"6","key":"10.1016\/j.actbio.2025.07.068_bib0013","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"issue":"6775","key":"10.1016\/j.actbio.2025.07.068_bib0014","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/35005107","article-title":"An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells","volume":"404","author":"Hammond","year":"2000","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.actbio.2025.07.068_bib0015","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.3390\/jcm9062004","article-title":"Antisense oligonucleotides: an emerging area in drug discovery and development","volume":"9","author":"Dhuri","year":"2020","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.actbio.2025.07.068_bib0016","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/00003495-199957030-00010","article-title":"Fomivirsen","volume":"57","author":"Perry","year":"1999","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.actbio.2025.07.068_bib0017","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40265-023-01904-6","article-title":"Tofersen: first approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.actbio.2025.07.068_bib0018","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of antisense oligonucleotide Tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.actbio.2025.07.068_bib0019","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1474-4422(24)00259-X","article-title":"Tofersen for SOD-1-associated amyotrophic lateral sclerosis","volume":"23","author":"Haberkamp","year":"2024","journal-title":"Lancet Neurol."},{"issue":"6669","key":"10.1016\/j.actbio.2025.07.068_bib0020","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.actbio.2025.07.068_bib0021","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrd2742","article-title":"Knocking down barriers: advances in siRNA delivery","volume":"8","author":"Whitehead","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.actbio.2025.07.068_bib0022","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ymthe.2024.01.005","article-title":"The landscape of nanoparticle-based siRNA delivery and therapeutic development","volume":"32","author":"Moazzam","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.actbio.2025.07.068_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174178","article-title":"siRNA: mechanism of action, challenges, and therapeutic approaches","volume":"905","author":"Alshaer","year":"2021","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.actbio.2025.07.068_bib0024","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"25","key":"10.1016\/j.actbio.2025.07.068_bib0025","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1182\/blood.2024027008","article-title":"Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study","volume":"145","author":"Young","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0026","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0027","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/ijms19010065","article-title":"Development of novel therapeutic agents by inhibition of oncogenic MicroRNAs","volume":"19","author":"Nguyen","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.actbio.2025.07.068_bib0028","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1038\/mtna.2015.23","article-title":"siRNA versus miRNA as therapeutics for gene silencing","volume":"4","author":"Lam","year":"2015","journal-title":"Mol. Ther. Nucleic. Acids."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0029","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cell.2018.03.006","article-title":"Metazoan MicroRNAs","volume":"173","author":"Bartel","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.actbio.2025.07.068_bib0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2015.05.001","article-title":"An overview of microRNAs","volume":"87","author":"Hammond","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"11","key":"10.1016\/j.actbio.2025.07.068_bib0031","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrc1997","article-title":"MicroRNA signatures in human cancers","volume":"6","author":"Calin","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.actbio.2025.07.068_bib0032","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.canlet.2017.04.007","article-title":"microRNAs as cancer therapeutics: a step closer to clinical application","volume":"407","author":"Catela Ivkovic","year":"2017","journal-title":"Cancer Lett."},{"issue":"10432","key":"10.1016\/j.actbio.2025.07.068_bib0033","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S0140-6736(23)02444-3","article-title":"mRNA-based therapeutics: looking beyond COVID-19 vaccines","volume":"403","author":"Parhiz","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.actbio.2025.07.068_bib0034","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ymthe.2020.09.028","article-title":"CRISPR-Cas9: a preclinical and clinical perspective for the treatment of Human diseases","volume":"29","author":"Sharma","year":"2021","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.actbio.2025.07.068_bib0035","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1056\/NEJMc2119358","article-title":"Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection","volume":"386","author":"Nemet","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.actbio.2025.07.068_bib0036","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJMoa2200674","article-title":"Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine","volume":"386","author":"Moreira","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.actbio.2025.07.068_bib0037","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.cell.2024.01.042","article-title":"Past, present, and future of CRISPR genome editing technologies","volume":"187","author":"Pacesa","year":"2024","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.actbio.2025.07.068_bib0038","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1021\/acs.nanolett.8b01101","article-title":"Lipid nanoparticle formulations for enhanced Co-delivery of siRNA and mRNA","volume":"18","author":"Ball","year":"2018","journal-title":"Nano Lett."},{"issue":"8","key":"10.1016\/j.actbio.2025.07.068_bib0039","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.biotechadv.2013.04.007","article-title":"Aptamers: molecules of great potential","volume":"31","author":"Radom","year":"2013","journal-title":"Biotechnol. Adv."},{"issue":"7","key":"10.1016\/j.actbio.2025.07.068_bib0040","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrd3141","article-title":"Aptamers as therapeutics","volume":"9","author":"Keefe","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.actbio.2025.07.068_bib0041","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: current potential and challenges","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.actbio.2025.07.068_bib0042","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nrd1677","article-title":"Pegaptanib sodium","volume":"4","author":"Fine","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"issue":"15","key":"10.1016\/j.actbio.2025.07.068_bib0043","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s40265-023-01948-8","article-title":"Avacincaptad Pegol: first approval","volume":"83","author":"Kang","year":"2023","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.actbio.2025.07.068_bib0044","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.apsb.2023.01.017","article-title":"Recent progress of aptamer\u2012drug conjugates in cancer therapy","volume":"13","author":"He","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0045","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/s41392-024-01973-3","article-title":"Aptamer-drug conjugates-loaded bacteria for pancreatic cancer synergistic therapy","volume":"9","author":"Xiao","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.actbio.2025.07.068_bib0046","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.healun.2015.08.012","article-title":"ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients","volume":"35","author":"Gottlieb","year":"2016","journal-title":"J. Heart Lung Trans. Plant"},{"issue":"8","key":"10.1016\/j.actbio.2025.07.068_bib0047","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/ppul.23707","article-title":"Highlights from the 2016 North American cystic fibrosis conference","volume":"52","author":"Zemanick","year":"2017","journal-title":"Pediatr. Pulmonol."},{"issue":"4","key":"10.1016\/j.actbio.2025.07.068_bib0048","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jcf.2023.04.008","article-title":"Inhaled mRNA therapy for treatment of cystic fibrosis: interim results of a randomized, double-blind, placebo-controlled phase 1\/2 clinical study","volume":"22","author":"Rowe","year":"2023","journal-title":"J. Cyst. Fibros."},{"issue":"3","key":"10.1016\/j.actbio.2025.07.068_bib0049","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1039\/D4TB01938E","article-title":"Nebulized inhalation drug delivery: clinical applications and advancements in research","volume":"13","author":"Yan","year":"2025","journal-title":"J. Mater. Chem. B"},{"issue":"6","key":"10.1016\/j.actbio.2025.07.068_bib0050","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1365-2125.2003.01893.x","article-title":"Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.actbio.2025.07.068_bib0051","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jconrel.2025.01.017","article-title":"The (re)emergence of aerosol delivery: treatment of pulmonary diseases and its clinical challenges","volume":"379","author":"Ghanem","year":"2025","journal-title":"J. Control Release"},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0052","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0378-5173(97)00105-1","article-title":"Ultrasonic nebulisers for pulmonary drug delivery","volume":"153","author":"Taylor","year":"1997","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0053","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4155\/tde-2021-0070","article-title":"Nebulizer systems: a new frontier for therapeutics and targeted delivery","volume":"13","author":"Khairnar","year":"2022","journal-title":"Ther. Deliv."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0054","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrd2153","article-title":"Inhaling medicines: delivering drugs to the body through the lungs","volume":"6","author":"Patton","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10\u201311","key":"10.1016\/j.actbio.2025.07.068_bib0055","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.addr.2011.05.017","article-title":"Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles","volume":"63","author":"Cai","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"6","key":"10.1016\/j.actbio.2025.07.068_bib0056","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03338-2020","article-title":"T.s. investigators, the effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCS randomised controlled trial","volume":"57","author":"Jenkins","year":"2021","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.actbio.2025.07.068_bib0057","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01892.x","article-title":"Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.actbio.2025.07.068_bib0058","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s41030-017-0046-2","article-title":"Improving the efficiency of Respiratory drug delivery: a review of current treatment trends and future strategies for asthma and chronic obstructive pulmonary disease","volume":"3","author":"Shakshuki","year":"2017","journal-title":"Pulm. Ther."},{"issue":"9","key":"10.1016\/j.actbio.2025.07.068_bib0059","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.3390\/pharmaceutics14091974","article-title":"A review of non-invasive drug delivery through Respiratory routes","volume":"14","author":"Zhang","year":"2022","journal-title":"Pharmaceutics."},{"issue":"17","key":"10.1016\/j.actbio.2025.07.068_bib0060","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1007\/s40265-023-01950-0","article-title":"Current and future treatment landscape for idiopathic pulmonary fibrosis","volume":"83","author":"Bonella","year":"2023","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0061","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/jamp.2018.1507","article-title":"Double-blinded, placebo-controlled, dose-escalation phase 1 study of aerosolized pirfenidone delivered via the PARI investigational eFlow nebulizer in volunteers and patients with idiopathic pulmonary fibrosis","volume":"33","author":"Khoo","year":"2020","journal-title":"J. Aerosol. Med. Pulm. Drug Deliv."},{"issue":"9","key":"10.1016\/j.actbio.2025.07.068_bib0062","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1136\/thorax-2022-219391","article-title":"Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose-response trial","volume":"78","author":"West","year":"2023","journal-title":"Thorax."},{"key":"10.1016\/j.actbio.2025.07.068_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105233","article-title":"Development of human respiratory airway models: a review","volume":"145","author":"Ahookhosh","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.actbio.2025.07.068_bib0064","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.apsb.2021.08.009","article-title":"Pulmonary delivery of siRNA against acute lung injury\/acute respiratory distress syndrome","volume":"12","author":"Zoulikha","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"5","key":"10.1016\/j.actbio.2025.07.068_bib0065","doi-asserted-by":"crossref","first-page":"311","DOI":"10.4155\/tde-2019-0012","article-title":"Nanocarriers in effective pulmonary delivery of siRNA: current approaches and challenges","volume":"10","author":"Bardoliwala","year":"2019","journal-title":"Ther. Deliv."},{"issue":"13","key":"10.1016\/j.actbio.2025.07.068_bib0066","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1016\/j.biomaterials.2013.01.064","article-title":"Nanoparticle diffusion in respiratory mucus from humans without lung disease","volume":"34","author":"Schuster","year":"2013","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.actbio.2025.07.068_bib0067","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.3390\/ijms24021694","article-title":"Nebulized menthol impairs mucociliary clearance via TRPM8 and MUC5AC\/MUC5B in primary airway epithelial cells","volume":"24","author":"Baumlin","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"21","key":"10.1016\/j.actbio.2025.07.068_bib0068","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202008960","article-title":"Pro-peptide-reinforced, mucus-penetrating pulmonary siRNA delivery mitigates cytokine storm in pneumonia","volume":"31","author":"Yang","year":"2021","journal-title":"Adv. Funct. Mater."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0069","article-title":"Advanced strategies to evade the mononuclear phagocyte system clearance of nanomaterials","volume":"3","author":"Lu","year":"2023","journal-title":"Exploration. (Beijing)"},{"issue":"7","key":"10.1016\/j.actbio.2025.07.068_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104019","article-title":"Impact of the diseased lung microenvironment on the in vivo fate of inhaled particles","volume":"29","author":"Gai","year":"2024","journal-title":"Drug Discov. Today"},{"issue":"3","key":"10.1016\/j.actbio.2025.07.068_bib0071","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1513\/AnnalsATS.201802-128AW","article-title":"Airway epithelial differentiation and mucociliary clearance","volume":"15","author":"Whitsett","year":"2018","journal-title":"Ann. Am. Thorac. Soc."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0072","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/thoraxjnl-2020-216296","article-title":"Cigarette smoke exposure and alveolar macrophages: mechanisms for lung disease","volume":"77","author":"Lugg","year":"2022","journal-title":"Thorax."},{"key":"10.1016\/j.actbio.2025.07.068_bib0073","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jconrel.2020.11.005","article-title":"Pulmonary siRNA delivery for lung disease: review of recent progress and challenges","volume":"330","author":"Ding","year":"2021","journal-title":"J. Control Release"},{"issue":"3","key":"10.1016\/j.actbio.2025.07.068_bib0074","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202412866","article-title":"Self-assembled eutectogel with cell permeation and multiple anti-inflammatory abilities for treating chronic periodontitis","volume":"37","author":"Cheng","year":"2025","journal-title":"Adv. Mater."},{"issue":"12","key":"10.1016\/j.actbio.2025.07.068_bib0075","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1016\/j.cclet.2020.07.030","article-title":"Magnetofection: magic magnetic nanoparticles for efficient gene delivery","volume":"31","author":"Bi","year":"2020","journal-title":"Chin. Chem. Lett."},{"issue":"9","key":"10.1016\/j.actbio.2025.07.068_bib0076","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1039\/D0CS01127D","article-title":"Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine","volume":"50","author":"Sousa de Almeida","year":"2021","journal-title":"Chem. Soc. Rev."},{"issue":"18","key":"10.1016\/j.actbio.2025.07.068_bib0077","doi-asserted-by":"crossref","DOI":"10.4028\/b-wjQRP6","article-title":"Recent progress in nucleic acid pulmonary delivery toward overcoming physiological barriers and improving transfection efficiency","volume":"11","author":"Wang","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"issue":"27","key":"10.1016\/j.actbio.2025.07.068_bib0078","doi-asserted-by":"crossref","first-page":"8382","DOI":"10.1021\/acs.langmuir.2c00952","article-title":"Polyethylenimine-DNA nanoparticles under endosomal acidification and implication to gene delivery","volume":"38","author":"Mahajan","year":"2022","journal-title":"Langmuir."},{"issue":"3","key":"10.1016\/j.actbio.2025.07.068_bib0079","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1208\/s12248-022-00698-x","article-title":"Targeted delivery of endosomal escape peptides to enhance immunotoxin potency and anti-cancer efficacy","volume":"24","author":"Polli","year":"2022","journal-title":"AAPS. J."},{"issue":"8","key":"10.1016\/j.actbio.2025.07.068_bib0080","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1631\/jzus.B2000808","article-title":"Toll-like receptor 3 (TLR3) regulation mechanisms and roles in antiviral innate immune responses","volume":"22","author":"Chen","year":"2021","journal-title":"J. Zhejiang. Univ. Sci. B"},{"key":"10.1016\/j.actbio.2025.07.068_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106860","article-title":"Peptide nucleic acids: recent developments in the synthesis and backbone modifications","volume":"141","author":"Singh","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.actbio.2025.07.068_bib0082","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.omtn.2019.12.011","article-title":"Chemical diversity of locked nucleic acid-modified antisense oligonucleotides allows optimization of pharmaceutical properties","volume":"19","author":"Papargyri","year":"2020","journal-title":"Mol. Ther. Nucleic. Acids."},{"issue":"2","key":"10.1016\/j.actbio.2025.07.068_bib0083","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s41061-017-0131-x","article-title":"Polymer-nucleic acid interactions","volume":"375","author":"Shen","year":"2017","journal-title":"Top. Curr. Chem. (Cham)"},{"issue":"12","key":"10.1016\/j.actbio.2025.07.068_bib0084","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3390\/biom11121809","article-title":"Novel approaches in biomolecule labeling","volume":"11","author":"Sabot","year":"2021","journal-title":"Biomolecules."},{"key":"10.1016\/j.actbio.2025.07.068_bib0085","article-title":"RNA-cholesterol nanoparticles function as potent immune activators via TLR7 and TLR8","volume":"12","author":"Obermann","year":"2021","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.actbio.2025.07.068_bib0086","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1093\/nar\/gkad415","article-title":"Targeted tissue delivery of RNA therapeutics using antibody-oligonucleotide conjugates (AOCs)","volume":"51","author":"Malecova","year":"2023","journal-title":"Nucleic. Acids. Res."},{"key":"10.1016\/j.actbio.2025.07.068_bib0087","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114038","article-title":"Nanoparticles for local delivery of siRNA in lung therapy","volume":"179","author":"Kubczak","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.actbio.2025.07.068_bib0088","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.3390\/pharmaceutics15051457","article-title":"Lipid-based inhalable micro- and nanocarriers of active agents for treating non-small-cell lung cancer","volume":"15","author":"Gandhi","year":"2023","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.actbio.2025.07.068_bib0089","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119338","article-title":"Developing spray-freeze-dried particles containing a hyaluronic acid-coated liposome-protamine-DNA complex for pulmonary inhalation","volume":"583","author":"Fukushige","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"51","key":"10.1016\/j.actbio.2025.07.068_bib0090","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202303261","article-title":"Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy","volume":"35","author":"Zong","year":"2023","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0091","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1038\/s41467-019-13094-5","article-title":"An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases","volume":"10","author":"Liu","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2025.07.068_bib0092","doi-asserted-by":"crossref","DOI":"10.1016\/j.cis.2023.102903","article-title":"Lessons from the history of inorganic nanoparticles for inhalable diagnostics and therapeutics","volume":"315","author":"Uskokovic","year":"2023","journal-title":"Adv. Colloid. Interface Sci."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0093","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s40364-024-00686-7","article-title":"New strategies for lung cancer diagnosis and treatment: applications and advances in nanotechnology","volume":"12","author":"Feng","year":"2024","journal-title":"Biomark. Res."},{"issue":"2","key":"10.1016\/j.actbio.2025.07.068_bib0094","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/smll.201401284","article-title":"Nebulized gadolinium-based nanoparticles: a theranostic approach for lung tumor imaging and radiosensitization","volume":"11","author":"Dufort","year":"2015","journal-title":"Small."},{"issue":"3","key":"10.1016\/j.actbio.2025.07.068_bib0095","doi-asserted-by":"crossref","DOI":"10.1002\/VIW.20200119","article-title":"In vivo CT imaging tracking of stem cells labeled with Au nanoparticles","volume":"3","author":"Huang","year":"2021","journal-title":"View"},{"key":"10.1016\/j.actbio.2025.07.068_bib0096","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.2147\/IJN.S398254","article-title":"Albumin-modified gold nanoparticles as novel radiosensitizers for enhancing lung cancer radiotherapy","volume":"18","author":"Chen","year":"2023","journal-title":"Int. J. Nanomedicine"},{"issue":"3","key":"10.1016\/j.actbio.2025.07.068_bib0097","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3390\/pharmaceutics16030347","article-title":"State-of-the-art Review on inhalable lipid and polymer nanocarriers: design and development perspectives","volume":"16","author":"Costabile","year":"2024","journal-title":"Pharmaceutics."},{"issue":"2","key":"10.1016\/j.actbio.2025.07.068_bib0098","doi-asserted-by":"crossref","first-page":"e1849","DOI":"10.1002\/wnan.1849","article-title":"Nanomedicine and nanobiotechnology applications of magnetoelectric nanoparticles","volume":"15","author":"Smith","year":"2023","journal-title":"Wiley. Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"issue":"3","key":"10.1016\/j.actbio.2025.07.068_bib0099","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s44222-024-00257-3","article-title":"Imaging-guided precision hyperthermia with magnetic nanoparticles","volume":"3","author":"Shakeri-Zadeh","year":"2025","journal-title":"Nat. Rev. Bioeng."},{"key":"10.1016\/j.actbio.2025.07.068_bib0100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1743-8977-10-19","article-title":"Cellular uptake and localization of inhaled gold nanoparticles in lungs of mice with chronic obstructive pulmonary disease","volume":"10","author":"Geiser","year":"2013","journal-title":"Part Fibre Toxicol."},{"issue":"9","key":"10.1016\/j.actbio.2025.07.068_bib0101","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2023.109384","article-title":"Inhaled multilevel size-tunable, charge-reversible and mucus-traversing composite microspheres as trojan horse: enhancing lung deposition and tumor penetration","volume":"35","author":"Xiong","year":"2024","journal-title":"Chin. Chem. Lett."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0102","doi-asserted-by":"crossref","first-page":"237","DOI":"10.7150\/thno.21945","article-title":"Exosome theranostics: biology and translational medicine","volume":"8","author":"He","year":"2018","journal-title":"Theranostics."},{"issue":"9","key":"10.1016\/j.actbio.2025.07.068_bib0103","doi-asserted-by":"crossref","first-page":"4984","DOI":"10.3390\/ijms22094984","article-title":"Extracellular vesicles and asthma-more than just a Co-existence","volume":"22","author":"Alashkar Alhamwe","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0104","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41467-020-14344-7","article-title":"Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis","volume":"11","author":"Dinh","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2025.07.068_bib0105","article-title":"Promising therapeutic functions of bone marrow mesenchymal stem cells derived-exosome in asthma","volume":"2022","author":"Yuan","year":"2022","journal-title":"Can. Respir. J."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0106","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.yexcr.2017.12.021","article-title":"Mesenchymal stem cell exosomes promote immunosuppression of regulatory T cells in asthma","volume":"363","author":"Du","year":"2018","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.actbio.2025.07.068_bib0107","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2147\/JAA.S307165","article-title":"MiR-21-5p in macrophage-derived exosomes targets Smad7 to promote epithelial mesenchymal transition of airway epithelial cells","volume":"14","author":"Li","year":"2021","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.actbio.2025.07.068_bib0108","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124248","article-title":"A review on micro and nanoengineering in powder-based pulmonary drug delivery","volume":"659","author":"Pasero","year":"2024","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0109","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1038\/s41467-025-56448-y","article-title":"Targeted delivery of TGF-beta mRNA to murine lung parenchyma using one-component ionizable amphiphilic Janus Dendrimers","volume":"16","author":"Meshanni","year":"2025","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.actbio.2025.07.068_bib0110","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40005-019-00443-1","article-title":"Poly(lactic acid)\/poly(lactic-co-glycolic acid) particulate carriers for pulmonary drug delivery","volume":"49","author":"Emami","year":"2019","journal-title":"J. Pharm. Investig."},{"issue":"15","key":"10.1016\/j.actbio.2025.07.068_bib0111","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.7150\/thno.86310","article-title":"Inhalation of acidic nanoparticles prevents doxorubicin cardiotoxicity through improvement of lysosomal function","volume":"13","author":"Santin","year":"2023","journal-title":"Theranostics."},{"issue":"9","key":"10.1016\/j.actbio.2025.07.068_bib0112","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s41551-021-00786-x","article-title":"Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs","volume":"5","author":"Lokugamage","year":"2021","journal-title":"Nat. Biomed. Eng."},{"issue":"9","key":"10.1016\/j.actbio.2025.07.068_bib0113","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.3390\/biomedicines10092179","article-title":"Lipid nanoparticles as delivery vehicles for inhaled therapeutics","volume":"10","author":"Leong","year":"2022","journal-title":"Biomedicines."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0114","doi-asserted-by":"crossref","first-page":"9471","DOI":"10.1038\/s41467-024-53914-x","article-title":"Charge-assisted stabilization of lipid nanoparticles enables inhaled mRNA delivery for mucosal vaccination","volume":"15","author":"Liu","year":"2024","journal-title":"Nat. Commun."},{"issue":"45","key":"10.1016\/j.actbio.2025.07.068_bib0115","article-title":"Micro-nanocarriers based drug delivery technology for blood-brain barrier crossing and brain tumor targeting therapy","volume":"18","author":"Wang","year":"2022","journal-title":"Small."},{"key":"10.1016\/j.actbio.2025.07.068_bib0116","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1128582","article-title":"Exploiting endocytosis for transfection of mRNA for cytoplasmatic delivery using cationic gold nanoparticles","volume":"14","author":"Gusta","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.actbio.2025.07.068_bib0117","doi-asserted-by":"crossref","first-page":"5059","DOI":"10.2147\/IJN.S516840","article-title":"Cutting-edge progress in the acquisition, modification and therapeutic applications of exosomes for drug delivery","volume":"20","author":"Wang","year":"2025","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.actbio.2025.07.068_bib0118","doi-asserted-by":"crossref","DOI":"10.1016\/j.matdes.2020.108805","article-title":"Review of hybrid PLGA nanoparticles: future of smart drug delivery and theranostics medicine","volume":"193","author":"Ghitman","year":"2020","journal-title":"Mater. Des."},{"issue":"12","key":"10.1016\/j.actbio.2025.07.068_bib0119","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1038\/mtna.2013.66","article-title":"Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles","volume":"2","author":"Mui","year":"2013","journal-title":"Mol. Ther. Nucleic. Acids."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0120","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41541-023-00766-z","article-title":"Polyethylene glycol (PEG)-associated immune responses triggered by clinically relevant lipid nanoparticles in rats","volume":"8","author":"Wang","year":"2023","journal-title":"NPJ. Vacc."},{"issue":"26","key":"10.1016\/j.actbio.2025.07.068_bib0121","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202211420","article-title":"Optimizing lipid nanoparticles for delivery in primates","volume":"35","author":"Lam","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.actbio.2025.07.068_bib0122","doi-asserted-by":"crossref","DOI":"10.1016\/j.impact.2021.100310","article-title":"Remote effects and biodistribution of pulmonary instilled silver nanoparticles in mice","volume":"22","author":"Ferdous","year":"2021","journal-title":"NanoImpact."},{"issue":"2","key":"10.1016\/j.actbio.2025.07.068_bib0123","doi-asserted-by":"crossref","first-page":"tfae058","DOI":"10.1093\/toxres\/tfae058","article-title":"Short term biodistribution and in vivo toxicity assessment of intravenously injected pristine graphene oxide nanoflakes in SD rats","volume":"13","author":"De","year":"2024","journal-title":"Toxicol. Res. (Camb)"},{"key":"10.1016\/j.actbio.2025.07.068_bib0124","doi-asserted-by":"crossref","DOI":"10.3389\/fnano.2025.1512622","article-title":"Toxicity and biodistribution comparison of functionalized nanodiamonds, quantum dot nanocarbons and gold nanoparticles","volume":"7","author":"Alexander","year":"2025","journal-title":"Front. Nanotechnol."},{"issue":"23","key":"10.1016\/j.actbio.2025.07.068_bib0125","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1039\/D4NA00501E","article-title":"A comprehensive review of challenges and advances in exosome-based drug delivery systems","volume":"6","author":"Palakurthi","year":"2024","journal-title":"Nanoscale Adv."},{"issue":"3","key":"10.1016\/j.actbio.2025.07.068_bib0126","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3390\/pharmaceutics13030427","article-title":"Biodistribution and pharmacokinectics of liposomes and exosomes in a mouse model of sepsis","volume":"13","author":"Mirzaaghasi","year":"2021","journal-title":"Pharmaceutics."},{"issue":"8","key":"10.1016\/j.actbio.2025.07.068_bib0127","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12085","article-title":"Biodistribution of extracellular vesicles following administration into animals: a systematic review","volume":"10","author":"Kang","year":"2021","journal-title":"J. ExtraCell Vesicles."},{"issue":"6","key":"10.1016\/j.actbio.2025.07.068_bib0128","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1021\/acs.molpharmaceut.6b00036","article-title":"Effect of the route of administration and PEGylation of poly(amidoamine) dendrimers on their systemic and lung cellular biodistribution","volume":"13","author":"Zhong","year":"2016","journal-title":"Mol. Pharm."},{"issue":"9","key":"10.1016\/j.actbio.2025.07.068_bib0129","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3390\/biom9090475","article-title":"Biodistribution and biosafety of a poly(Phosphorhydrazone) dendrimer, an anti-inflammatory drug-candidate","volume":"9","author":"Fruchon","year":"2019","journal-title":"Biomolecules."},{"issue":"10","key":"10.1016\/j.actbio.2025.07.068_bib0130","first-page":"3244","article-title":"Dendrimer-decorated nanogels: efficient nanocarriers for biodistribution in vivo and chemotherapy of ovarian carcinoma","volume":"6","author":"Li","year":"2021","journal-title":"Bioact. Mater."},{"issue":"5","key":"10.1016\/j.actbio.2025.07.068_bib0131","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.3390\/ijms24054333","article-title":"PLGA-based micro\/nanoparticles: an overview of their applications in Respiratory diseases","volume":"24","author":"Guo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.actbio.2025.07.068_bib0132","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108757","article-title":"Pathology of idiopathic pulmonary fibrosis with particular focus on vascular endothelium and epithelial injury and their therapeutic potential","volume":"265","author":"Lu","year":"2025","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.actbio.2025.07.068_bib0133","article-title":"Idiopathic Pulmonary Fibrosis: an update on pathogenesis","volume":"12","author":"Mei","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0134","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12931-021-01791-z","article-title":"Global incidence and prevalence of idiopathic pulmonary fibrosis","volume":"22","author":"Maher","year":"2021","journal-title":"Respir. Res."},{"key":"10.1016\/j.actbio.2025.07.068_bib0135","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jconrel.2022.05.039","article-title":"Novel drug delivery systems and disease models for pulmonary fibrosis","volume":"348","author":"Li","year":"2022","journal-title":"J. Control Release"},{"issue":"9685","key":"10.1016\/j.actbio.2025.07.068_bib0136","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(09)60551-1","article-title":"Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial","volume":"374","author":"King","year":"2009","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.actbio.2025.07.068_bib0137","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1183\/09031936.00104612","article-title":"Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial","volume":"42","author":"Raghu","year":"2013","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0138","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1164\/rccm.201011-1874OC","article-title":"BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis","volume":"184","author":"King","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0139","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1164\/rccm.201202-0314OC","article-title":"N. Idiopathic Pulmonary Fibrosis Clinical Research, A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis","volume":"186","author":"Noth","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"22","key":"10.1016\/j.actbio.2025.07.068_bib0140","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1401739","article-title":"Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis","volume":"370","author":"Martinez","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.actbio.2025.07.068_bib0141","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1002110","article-title":"A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis","volume":"363","author":"Idiopathic Pulmonary Fibrosis Clinical Research","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.actbio.2025.07.068_bib0142","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis","volume":"366","author":"Raghu","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.actbio.2025.07.068_bib0143","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev-pathol-042320-030240","article-title":"Pathogenic mechanisms underlying idiopathic pulmonary fibrosis","volume":"17","author":"Moss","year":"2022","journal-title":"Annu Rev. Pathol."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0144","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12931-024-02878-z","article-title":"Current state of signaling pathways associated with the pathogenesis of idiopathic pulmonary fibrosis","volume":"25","author":"Zhou","year":"2024","journal-title":"Respir. Res."},{"issue":"3","key":"10.1016\/j.actbio.2025.07.068_bib0145","article-title":"Spatiotemporal single-cell transcriptomic profiling reveals inflammatory cell states in a mouse model of diffuse alveolar damage","volume":"3","author":"Su","year":"2023","journal-title":"Exploration. (Beijing)"},{"issue":"511","key":"10.1016\/j.actbio.2025.07.068_bib0146","doi-asserted-by":"crossref","first-page":"eaaw1237","DOI":"10.1126\/scitranslmed.aaw1237","article-title":"Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis","volume":"11","author":"Ng","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"25","key":"10.1016\/j.actbio.2025.07.068_bib0147","doi-asserted-by":"crossref","first-page":"eabn7162","DOI":"10.1126\/sciadv.abn7162","article-title":"Inhaled siRNA nanoparticles targeting IL11 inhibit lung fibrosis and improve pulmonary function post-bleomycin challenge","volume":"8","author":"Bai","year":"2022","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0148","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1038\/s41467-024-51056-8","article-title":"Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy","volume":"15","author":"Bai","year":"2024","journal-title":"Nat. Commun."},{"issue":"14","key":"10.1016\/j.actbio.2025.07.068_bib0149","article-title":"Inhaled mRNA nanoformulation with biogenic ribosomal protein reverses established pulmonary fibrosis in a bleomycin-induced murine model","volume":"34","author":"Zhang","year":"2022","journal-title":"Adv. Mater."},{"issue":"24","key":"10.1016\/j.actbio.2025.07.068_bib0150","doi-asserted-by":"crossref","first-page":"eado4791","DOI":"10.1126\/sciadv.ado4791","article-title":"Realveolarization with inhalable mucus-penetrating lipid nanoparticles for the treatment of pulmonary fibrosis in mice","volume":"10","author":"Wang","year":"2024","journal-title":"Sci. Adv."},{"issue":"21","key":"10.1016\/j.actbio.2025.07.068_bib0151","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1001\/jama.2023.8120","article-title":"Cystic Fibrosis: a review","volume":"329","author":"Ong","year":"2023","journal-title":"JAMa"},{"key":"10.1016\/j.actbio.2025.07.068_bib0152","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"The changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0153","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","article-title":"Cystic fibrosis","volume":"10","author":"Mall","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0154","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1146\/annurev-med-042120-020148","article-title":"Clinical phenotypes of cystic fibrosis carriers","volume":"73","author":"Polgreen","year":"2022","journal-title":"Annu. Rev. Med."},{"issue":"3","key":"10.1016\/j.actbio.2025.07.068_bib0155","doi-asserted-by":"crossref","DOI":"10.3390\/ph16030410","article-title":"Elexacaftor-Tezacaftor-Ivacaftor: a life-changing triple combination of CFTR modulator drugs for cystic fibrosis","volume":"16","author":"Bacalhau","year":"2023","journal-title":"Pharmaceuticals. (Basel)"},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0156","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41467-023-36244-2","article-title":"Future therapies for cystic fibrosis","volume":"14","author":"Allen","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0157","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev-publhealth-052120-012811","article-title":"Health-related quality of life measurement in public Health","volume":"43","author":"Kaplan","year":"2022","journal-title":"Annu. Rev. Public Health"},{"issue":"9","key":"10.1016\/j.actbio.2025.07.068_bib0158","doi-asserted-by":"crossref","first-page":"14792","DOI":"10.1021\/acsnano.2c05647","article-title":"Engineering lipid nanoparticles for enhanced intracellular delivery of mRNA through inhalation","volume":"16","author":"Kim","year":"2022","journal-title":"ACS. Nano"},{"issue":"4","key":"10.1016\/j.actbio.2025.07.068_bib0159","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jcf.2018.10.015","article-title":"Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis","volume":"18","author":"Sermet-Gaudelus","year":"2019","journal-title":"J. Cyst. Fibros."},{"issue":"2","key":"10.1016\/j.actbio.2025.07.068_bib0160","article-title":"From structural design to delivery: mRNA therapeutics for cancer immunotherapy","volume":"4","author":"Zhou","year":"2024","journal-title":"Exploration. (Beijing)"},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0161","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1038\/s41467-023-42948-2","article-title":"Lung SORT LNPs enable precise homology-directed repair mediated CRISPR\/Cas genome correction in cystic fibrosis models","volume":"14","author":"Wei","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2025.07.068_bib0162","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jconrel.2014.01.007","article-title":"Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier","volume":"178","author":"Suk","year":"2014","journal-title":"J. Control Release"},{"key":"10.1016\/j.actbio.2025.07.068_bib0163","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD), Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2024."},{"issue":"9823","key":"10.1016\/j.actbio.2025.07.068_bib0164","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60968-9","article-title":"Chronic obstructive pulmonary disease","volume":"379","author":"Decramer","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.actbio.2025.07.068_bib0165","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-069679","article-title":"Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019","volume":"378","author":"Safiri","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.actbio.2025.07.068_bib0166","unstructured":"World Health Organization, Projections of global deaths from 2016 to 2060, 2022. https:\/\/colinmathers.com\/2022\/05\/10\/projections-of-global-deaths-from-2016-to-2060\/. (Accessed Oct 2023)."},{"issue":"5","key":"10.1016\/j.actbio.2025.07.068_bib0167","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S2213-2600(21)00506-3","article-title":"Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment","volume":"10","author":"Yang","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.actbio.2025.07.068_bib0168","article-title":"Variants of SERPINA1 and the increasing complexity of testing for alpha-1 antitrypsin deficiency","volume":"12","author":"Foil","year":"2021","journal-title":"Ther. Adv. Chronic. Dis."},{"issue":"10","key":"10.1016\/j.actbio.2025.07.068_bib0169","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.ajhg.2023.08.017","article-title":"The COPD GWAS gene ADGRG6 instructs function and injury response in human iPSC-derived type II alveolar epithelial cells","volume":"110","author":"Werder","year":"2023","journal-title":"Am. J. Hum. Genet."},{"issue":"5","key":"10.1016\/j.actbio.2025.07.068_bib0170","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1165\/rcmb.2021-0016OC","article-title":"Connecting COPD GWAS genes: FAM13A controls TGFbeta2 secretion by modulating AP-3 transport","volume":"65","author":"Gong","year":"2021","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"3","key":"10.1016\/j.actbio.2025.07.068_bib0171","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1164\/rccm.201609-1830OC","article-title":"Role for NLRP3 inflammasome-mediated, IL-1beta-dependent responses in severe, steroid-resistant asthma","volume":"196","author":"Kim","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.actbio.2025.07.068_bib0172","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev.physiol.010908.163257","article-title":"Role of HDAC2 in the pathophysiology of COPD","volume":"71","author":"Barnes","year":"2009","journal-title":"Annu. Rev. Physiol."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0173","first-page":"20","article-title":"miR-21 antagomir reverses COPD pathology","volume":"21","author":"Crunkhorn","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"621","key":"10.1016\/j.actbio.2025.07.068_bib0174","doi-asserted-by":"crossref","first-page":"eaav7223","DOI":"10.1126\/scitranslmed.aav7223","article-title":"A microRNA-21-mediated SATB1\/S100A9\/NF-kappaB axis promotes chronic obstructive pulmonary disease pathogenesis","volume":"13","author":"Kim","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.actbio.2025.07.068_bib0175","doi-asserted-by":"crossref","first-page":"5470","DOI":"10.18632\/oncotarget.6562","article-title":"Chronic NF-kappaB activation links COPD and lung cancer through generation of an immunosuppressive microenvironment in the lungs","volume":"7","author":"Zaynagetdinov","year":"2016","journal-title":"Oncotarget."},{"issue":"3","key":"10.1016\/j.actbio.2025.07.068_bib0176","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/ars.2019.7975","article-title":"Nuclear factor kappa B signaling complexes in acute inflammation","volume":"33","author":"Rius-Perez","year":"2020","journal-title":"Antioxid. Redox. Signal."},{"key":"10.1016\/j.actbio.2025.07.068_bib0177","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.omtn.2018.05.027","article-title":"Ribosomal protein S3 gene silencing protects against cigarette smoke-induced acute lung injury","volume":"12","author":"Dong","year":"2018","journal-title":"Mol. Ther. Nucleic. Acids."},{"issue":"12","key":"10.1016\/j.actbio.2025.07.068_bib0178","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167169","article-title":"MAP3K19 Is overexpressed in COPD and Is a Central mediator of cigarette smoke-induced pulmonary inflammation and lower airway destruction","volume":"11","author":"Boehme","year":"2016","journal-title":"PLoS. One"},{"issue":"48","key":"10.1016\/j.actbio.2025.07.068_bib0179","doi-asserted-by":"crossref","first-page":"28989","DOI":"10.18632\/oncotarget.25615","article-title":"The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target","volume":"9","author":"Goldenberg","year":"2018","journal-title":"Oncotarget."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0180","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12931-018-0834-8","article-title":"Epithelial mesenchymal transition (EMT): a universal process in lung diseases with implications for cystic fibrosis pathophysiology","volume":"19","author":"Rout-Pitt","year":"2018","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0181","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12931-016-0463-z","article-title":"Increased expression of TROP2 in airway basal cells potentially contributes to airway remodeling in chronic obstructive pulmonary disease","volume":"17","author":"Liu","year":"2016","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0182","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1164\/rccm.202109-2205PP","article-title":"Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes","volume":"205","author":"Reddel","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.actbio.2025.07.068_bib0183","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114858","article-title":"Inhaled drug delivery for the targeted treatment of asthma","volume":"198","author":"Boboltz","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.actbio.2025.07.068_bib0184","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jaci.2021.09.023","article-title":"Housing and asthma disparities","volume":"148","author":"Bryant-Stephens","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.actbio.2025.07.068_bib0185","first-page":"S2","article-title":"Asthma: definitions and pathophysiology","volume":"5","author":"Mims","year":"2015","journal-title":"Int. Forum. Allergy Rhinol."},{"issue":"2","key":"10.1016\/j.actbio.2025.07.068_bib0186","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","article-title":"Understanding asthma phenotypes, endotypes, and mechanisms of disease","volume":"56","author":"Kuruvilla","year":"2019","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.actbio.2025.07.068_bib0187","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112189","article-title":"Precision medicine for severe asthma - biological targeted therapy","volume":"134","author":"Sun","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.actbio.2025.07.068_bib0188","article-title":"A first-In-Human study of ARO-RAGE, A novel inhaled RNA-interference therapy for asthma","volume":"209","author":"O'Carroll","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.actbio.2025.07.068_bib0189","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.ajpath.2012.06.031","article-title":"The receptor for advanced glycation end products is a central mediator of asthma pathogenesis","volume":"181","author":"Milutinovic","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.actbio.2025.07.068_bib0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108432","article-title":"The mixture of siRNAs targeted to IL-4 and IL-13 genes effectively reduces the airway hyperreactivity and allergic inflammation in a mouse model of asthma","volume":"103","author":"Ip","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.actbio.2025.07.068_bib0191","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jconrel.2022.10.020","article-title":"Airway epithelial cell-specific delivery of lipid nanoparticles loading siRNA for asthma treatment","volume":"352","author":"Zhang","year":"2022","journal-title":"J. Control Release"},{"issue":"2","key":"10.1016\/j.actbio.2025.07.068_bib0192","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s13346-023-01402-y","article-title":"Inhalable dry powder product (DPP) of mRNA lipid nanoparticles (LNPs) for pulmonary delivery","volume":"14","author":"Sarode","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.actbio.2025.07.068_bib0193","article-title":"A deep generative model for the design of synthesizable ionizable lipids","author":"Ou","year":"2024","journal-title":"ArXiv."},{"key":"10.1016\/j.actbio.2025.07.068_bib0194","article-title":"Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy","author":"Witten","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.actbio.2025.07.068_bib0195","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.696668","article-title":"Organoid technology: a reliable developmental biology tool for organ-specific nanotoxicity evaluation","volume":"9","author":"Prasad","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"9","key":"10.1016\/j.actbio.2025.07.068_bib0196","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41565-020-0723-4","article-title":"Engineering synthetic breath biomarkers for respiratory disease","volume":"15","author":"Chan","year":"2020","journal-title":"Nat. Nanotechnol."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S174270612500577X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S174270612500577X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:22:19Z","timestamp":1772893339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S174270612500577X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":196,"alternative-id":["S174270612500577X"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2025.07.068","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhalable nucleic acid therapeutics for chronic pulmonary disease: Progress, challenges, and prospects","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2025.07.068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Acta Materialia Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}